Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Rating Reiterated by Piper Jaffray Companies

Zimmer Biomet Holdings, Inc. The institutional investor owned 17,782 shares of the medical equipment provider's stock after buying an additional 2,880 shares during the period. OppenheimerFunds Inc. owned about 1.22% of Zimmer Biomet Holdings worth $298,560,000 as of its most recent filing with the SEC. Glenview Capital Management LLC bought a new position in shares of Zimmer Biomet Holdings during the first quarter worth $94,197,000. Finally, GLG LLC raised its stake in shares of Zimmer Biomet Holdings by 6.8% in the fourth quarter. During the same quarter in the previous year, the firm earned $2.00 EPS. Hills Bank & Trust Co. increased its position in Zimmer Biomet Holdings by 7.7% in the first quarter. Levin Capital Strategies L.P. now owns 556,036 shares of the medical equipment provider's stock worth $57,383,000 after buying an additional 164,132 shares in the last quarter. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has "Buy" rating given on Wednesday, November 4 by Sterne Agee CRT. As of the last earnings report the EPS was $2.44 and is estimated to be $8.52 for the current year with 201,644,000 shares presently outstanding. Corporate insiders own 1.07% of the company's stock.

07/12/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Wells Fargo. Zacks downgraded the shares of ZBH in report on Friday, August 28 to "Buy" rating. The company's 50 day moving average price is $123.43 and its 200 day moving average price is $117.75.

Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.21. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings, Inc. with MarketBeat.com's FREE daily email newsletter. The medical equipment provider reported $2.13 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.11 by $0.02. The company had revenue of $1.98 billion for the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. Zimmer Biomet Holdings's revenue was up 3.8% compared to the same quarter past year. During the same quarter in the prior year, the company posted $2.00 earnings per share.

COPYRIGHT VIOLATION NOTICE: "Zimmer Biomet Holdings, Inc".

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 28th. The dividend payment will be $0.240 per share for the quarter or $0.96 on an annualized basis. The ex-dividend date will be Wednesday June 21st, 2017. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and global trademark and copyright law.

Analysts await Travelers Companies Inc (NYSE:TRV) to report earnings on July, 20 before the open. Canaccord Genuity reiterated a "buy" rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday.

07/12/2017 - Zimmer Biomet Holdings, Inc. was upgraded to " by analysts at Guggenheim.

On November 1 the stock rating was upgraded to "Strong Buy" from " in a report from Needham. BMO Capital Markets reissued a "buy" rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th.

On December 15, 2016 the stock rating was rated "Sell" according to a UBS report which is down from the previous " rating. They now have a United States dollars 137 price target on the stock. VP/Gen Counsel/Secretary sold $725,276 worth of shares at an average price of $116.98 on May 5th. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David C. Dvorak sold 87,331 shares of Zimmer Biomet Holdings stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. Following the completion of the transaction, the insider now owns 381,886 shares in the company, valued at $44,478,262.42. The disclosure for this sale can be found here.